Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegtibatinase - Travere Therapeutics

Next Previous
Drug Profile

Pegtibatinase - Travere Therapeutics

Alternative Names: htCBS C15S ME-200GS; OT-58; PEG htCBS C15S; PEG modified CBS; TVT-058

Latest Information Update: 04 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Technologies
  • Developer Orphan Technologies; Travere Therapeutics
  • Class Enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Homocystinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Homocystinuria

Most Recent Events

  • 27 Sep 2024 Travere Therapeutics suspends enrollment in the phase III HARMONY trial for Homocystinuria (SC)
  • 26 Sep 2024 Travere Therapeutics plans to restart the phase III HARMONY trial for homocystinuria in 2026 (SC)
  • 30 Apr 2024 Travere Therapeutics initiates enrolment by invitation in a phase IIIb trial for Homocystinuria (In adolescents, In adults) in USA (SC) (NCT06431893)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top